Teleflex Inc (TFX) FinancialsTFXTeleflex Inc

Teleflex Incorporated (TFX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Vascular access, accounting for 43.2% of total sales, equivalent to $246.34M. Other significant revenue streams include Interventional and Surgical. Understanding this composition is critical for investors evaluating how TFX navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Teleflex Incorporated maintains a gross margin of 58.16%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 8.43%, while the net margin is 7.32%. These profitability ratios, combined with a Return on Equity (ROE) of -0.70%, provide a clear picture of how effectively TFX converts its operational activities into shareholder value.

In the context of the broader market, TFX competes directly with industry leaders such as STVN and MMSI. With a market capitalization of $5.27B, it holds a leading position in the sector. When comparing efficiency, TFX's gross margin of 58.16% stands against STVN's 29.51% and MMSI's 51.37%. Such benchmarking helps identify whether Teleflex Incorporated is trading at a premium or discount relative to its financial performance.

Teleflex reported a gross margin of 58.16% in Q2 2026, indicating solid profitability. The company also showed a significant EPS surprise of 37.50% in its last earnings report, reflecting better-than-expected performance.